loader2
Login Open ICICI 3-in-1 Account
  • Text Size
  • Text to Speech
  • Color Contrast
  • Pause Animations

Open ICICI
3-in-1 Account

Manage your Savings, Demat and Trading Account conveniently at one place

+91

BLOG

Watershed movement for Indian Pharma- Wockhardt gets USFDA approval for an innovative drug, only second for an Indian company

ICICIdirect Research 05 Jun 2026 DISCLAIMER

The company over two decades has invested ~US$800 million into its proprietary antibiotic discovery program across six novel antibiotic molecules. The company faced severe liquidity crunch and has even divested 10 of its multi-specialty hospitals to Fortis to clear its debt.
After long gestation company is bearing fruits of its hard work as its Key antibiotic drug Zaynich has secured USFDA and CDSCO approval while European approval is expected in coming 4-6 months.
Zaynich is First Indian discovered NCE and company plans to roll out the product in the US, India, Europe and EM.  Company expects peak revenue potential of ~US$1.5-2 billion from the drug and it to capture ~25-30% of the global market share in the segment. The product is supported by 20% better efficacy than the existing cure with a strong safety profile and Broader coverage.
Beyond Zaynich, Wockhardt has 5 other similar assets under research pipeline in various phases which can be long term opportunities.  
While Zaynich's approval marks a landmark achievement for Wockhardt and the Indian pharmaceutical industry, it will also induce interest in other pharma companies which are perusing a step-by-step approach towards innovative drugs.
We expect a gradual shift from ‘generic-only’ strategy to a ‘generics+innovation’ strategy among leading Indian Pharma companies with a plenty of cash and cash equivalents at their disposal.
Top Pick: Dr Reddy - Target Price - ₹1460

Download ICICI Direct app

Invest, Track, and Manage your Portfolio Anytime, Anywhere

Download ICICI Direct app

Invest, Track, and Manage your Portfolio Anytime, Anywhere